Home > Healthcare > Drug Device Combination > Therapeutic Systems > Cervical Dysplasia Market

Cervical Dysplasia Market Trends

Report ID: GMI9898
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Cervical Dysplasia Market Trends

Increasing research activities and extending pipeline studies to develop innovative treatments for cervical disorders are driving market growth. These efforts address the growing concern for effective treatment options for cervical dysplasia and related conditions, thereby expanding the market by meeting the unmet needs of patients and healthcare providers seeking advanced therapeutic solutions.

For instance, in December 2021, INOVIO announced updates on its Phase 3 program for VGX-3100, a targeting HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL). The updates include a one-year follow-up of efficacy and safety data from REVEAL1, completion of enrolment in REVEAL2, and advancement of its pre-treatment biomarker candidate with QIAGEN. Similarly, INOVIO's development partner in Greater China, ApolloBio Corp., dosed the first participant in a separate Phase 3 trial in China. This innovative research aimed to treat HPV-associated cervical disorders through non-surgical methods.

Thus, availability of strong pipeline along with growing awareness for early immunizations with enhanced diagnostic technologies will propel the market demand.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cervical dysplasia market size was USD 675.5 million in 2023 and is expected to register 7.1% CAGR from 2024-2032 owing to the increasing prevalence of human papillomavirus (HPV) infections, which are closely linked to the development of cervical dysplasia worldwide.

Cervical dysplasia industry from the low-grade cervical dysplasia segment is expected to register 7.2% CAGR from 2024-2032 due to its higher prevalence compared to high-grade dysplasia.

The U.S. cervical dysplasia industry reached USD 272.1 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to advanced healthcare infrastructure, high prevalence of HPV infections, and widespread cervical cancer screening programs in the region.

Abbott Laboratories, Asieris Pharmaceuticals, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hologic Inc., Kinopharma, Merck & Co., Inc., OncoHealth Corporation, and Qiagen, are some of the major cervical dysplasia companies worldwide.